NCT05794477View on ClinicalTrials.gov

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

Adebrelimab

Specified dose on specified days

BIOLOGICAL

SHR-1802

Specified dose on specified days

DRUG

Carboplatin/Cisplatin

Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

DRUG

Paclitaxel/Nab-Paclitaxel/Pemetrexed

Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY